Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SciSparcSPRC -1.05%39 Debt-to-EBITDA is -0.04 as of Dec. 2025. GuruFocus rates SPRC with a GF Score™ of 39/100 and a GF Value™ of $3.03 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 316 Biotechnology companies, SciSparc ranks worse than 316455.38% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for SciSparc's Debt-to-EBITDA or its related term are showing as below:
SPRC'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.3 Med: -0.03 Max: -0.01
Current: -0.03
During the past 13 years, the highest Debt-to-EBITDA Ratio of SciSparc was -0.01. The lowest was -0.30. And the median was -0.03.
SPRC's Debt-to-EBITDA is ranked worse than 100% of 316
companies
in the Biotechnology industry
Industry Median: 1.255
vs SPRC: -0.03
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SciSparc Debt-to-EBITDA Related Terms
SciSparc Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for SciSparc's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SPRC vs ACUT, ONCO, PPCB: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, SciSparc's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SciSparc Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SciSparc's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SciSparc's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
SciSparc (SPRC) has a Debt-to-EBITDA of -0.04 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on SciSparc. According to the industry distribution chart, SciSparc ranks #999999 out of 316 companies in the Biotechnology industry.
Is SciSparc's Debt-to-EBITDA too high?
SciSparc's current Debt-to-EBITDA is -0.04. Based on the distribution chart, SciSparc ranks #999999 out of 316 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SciSparc has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SciSparc's Debt-to-EBITDA compare to ACUT and ONCO?
According to the Biotechnology industry distribution chart, SciSparc ranks #999999 out of 316 companies for Debt-to-EBITDA. This places SciSparc in the lower half of its industry. The industry median Debt-to-EBITDA is 1.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.26, based on 316 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on SciSparc. For the Biotechnology industry, the median Debt-to-EBITDA is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SciSparc's current Debt-to-EBITDA is -0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SciSparc stock overvalued right now?
Based on GuruFocus' analysis, SciSparc (SPRC) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.03, compared to a current price of $6.58 — trading 117.2% above its estimated fair value. The current Debt-to-EBITDA is -0.04. SciSparc's overall GF Score™ is 39/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For SciSparc (SPRC), the current Debt-to-EBITDA is -0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SciSparc (SPRC) Overvalued in 2026?
Based on GuruFocus' analysis, SciSparc stock appears to be overvalued.
The current stock price of $6.58 is trading 117.2% above its estimated GF Value™ of $3.03.
GuruFocus considers SciSparc to be Significantly Overvalued.
Key valuation signals for SPRC:
Debt-to-EBITDA: -0.04
GF Value™: $3.03 vs. price of $6.58 (117.2% above fair value)
No single metric tells the full story. See the SPRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
39GF Score
Get the complete analysis for SPRC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRC has been successfully added to your 
